Sulforaphane inhibits TGF-β-induced epithelial-mesenchymal transition of hepatocellular carcinoma cells via the reactive oxygen species-dependent pathway

JINSHENG WU1, JINGLI HAN2, BENXIN HOU3, CHENGWEI DENG1, HUANLIANG WU1 and LIANGFANG SHEN4

1Department of Oncology, Nonkennada Hospital, Danzhou, Hainan; 2The Sixth Affiliated Hospital of Xinjiang Medical University, Xinjiang; 3Department of General Surgery, The Third People's Hospital of Hainan Province, Hainan; 4Department of Oncology, Xiangya Hospital, Central South University, Hunan, P.R. China

Received November 24, 2015; Accepted December 31, 2015

DOI: 10.3892/or.2016.4638

Abstract. Sulforaphane is recognized as a safe antitumor agent derived from various cruciferous vegetables, including broccoli. It has been demonstrated that sulforaphane is a potent antitumor agent in diverse cancers. However, its effect on hepatocellular carcinoma remains largely unknown. Here, we show that sulforaphane inhibits TGF-β-induced epithelial-mesenchymal transition of hepatocellular carcinoma cell via the reactive oxygen species-dependent pathway. We found sulforaphane inhibited hepatocellular carcinoma cell proliferation in a dose- and time-dependent manner. Sulforaphane induced G0/G1 phase cell cycle arrest and promoted cell apoptosis. A set of experiments showed that sulforaphane inhibited hepatocellular carcinoma cell migration and invasion, inhibited the formation of fibroblast like mesenchymal cells and the expression of Vimentin, but increased the expression of E-cadherin, suggesting sulforaphane suppresses epithelial-mesenchymal transition (EMT) process. Cotreatment with N-acetyl-L-cysteine inhibited sulforaphane-inhibited invasion and upregulation of E-cadherin and almost completely abolished the sulforaphane-induced expression of Vimentin. The effect of sulforaphane on the growth of hepatocellular carcinoma cells was confirmed by a xenograft tumor growth model. All our finding indicated that sulforaphane is a promising and safe strategy for treating hepatocellular carcinoma.

Introduction

Liver cancer has high incidence worldwide, and especially in China (1). Hepatocellular carcinoma represents 70-90% of primary liver cancers occurring worldwide, it is highly aggressive with poor prognosis resulting in high mortality. Although the risk of liver cancer has been reduced with the use of antiviral treatment, they are costly and not in wide use (2,3), there are no well-established effective adjuvant therapies for hepatocellular carcinoma (4). Recent advances in understanding the molecular pathogenesis of hepatocellular carcinoma have shown great promise to develop more effective treatment for hepatocellular carcinoma (5,6). For this purpose, researchers have focused on the mechanism of hepatocellular carcinoma progression and metastasis, to identify better molecular targets and agents.

It has demonstrated that multiple steps are involved in the process of cancer progression and metastasis (7-9). Metastasis, one of the most complicated and major pathologic processes, is responsible for poor prognosis of cancer patients. Transforming growth factor β1 (TGF-β1) is one of the important cytokines involved. By stimulation of TGF-β, hepatocellular carcinoma HepG2 cells showed morphological, molecular and functional changes, including the formation of spindle shape, the loss of cell contact, and the downregulation of E-cadherin expression, but upregulation of Vimentin expression, showing a typical epithelial-mesenchymal transition (EMT) (10,11). EMT plays an important role in various cancer metastasis, and is thought to be a prerequisite for tumor cell invasion and metastasis (12-15). Although increased evidence shows that TGF-β could induce the EMT of various cancer cells and that EMT is pivotal for controlling tumor invasiveness and metastasis, the regulation mechanism of EMT is still unclear (16). Studies of the regulation mechanism of EMT are important for developing more effective anti-metastatic strategies.

Sulforaphane (SFN), a naturally occurring isothiocyanate derived from cruciferous vegetables, especially broccoli, which has been widely used for treatment of inflammatory diseases, shows antitumor effects in vitro and in vivo studies (17-20). Increased evidence shows that SFN is an important
candidate cancer preventive agent with high activity in diverse cancers, including thyroid cancer (17), breast cancer (19), colon cancer (21,22), prostate cancer (18), bladder cancer (23,24) and leukemia (25). Mechanically, it was demonstrated that SFN inhibited thyroid cancer cell growth and invasiveness, promoting mitochondrial-mediated apoptosis via reactive oxygen species (ROS)-dependent pathway (1). SFN induces apoptosis in bladder cancer cells through a ROS-mediated mitochondrial pathway (23,24). Although the antitumor effect of SFN on hepatocellular carcinoma remains unknown, ROS has been also reported to mediate many cellular effects of hepatoma cells, including the EMT of HepG2 cells induced by the tumor promoter 12-O-tetradecanoyl phorbol-13-acetate (26).

The purpose of this study was to evaluate the effect of SFN on cell apoptosis, migration and invasion of hepatocellular carcinoma, as well as EMT induced by TGF-β. We also tested whether ROS involved in the antitumor mechanisms of SFN by the ROS scavenger N-acetyl-L-cysteine (NAC) and to test its in vivo therapeutic potential in hepatocellular carcinoma.

Materials and methods

Cell culture. Human hepatocellular carcinoma cell line HepG2 was obtained from ATCC (Rockville, MD, USA). Cells were cultured in RPMI-1640 medium with 10% fetal bovine serum (FBS) at 37°C in a humidified atmosphere containing 5% CO₂ and experiments were done using 70-80% confluent cultures.

Cell proliferation assay. HepG2 cell survival was evaluated using the MTT (3-(4,5-dimethyl-thiazol-2-yl) 2,5-diphenyltetrazolium bromide) (Sigma, USA) colorimetric assay. After different doses (vehicle, 10, 20, 40, 60 and 80 µM) of SFN treatment for 48 h, MTT assay was performed on hepatocellular carcinoma cell line HepG2 to evaluate cell growth ability and to calculate the 50% inhibitory concentration of SFN. Then, the cell proliferation in the presence of indicated SFN (IC₅₀) or vehicle control for indicated time-points. In brief, prior to the treatment, HepG2 cells were seeded in 96-well tissue culture plates at 2x10⁴ cells per well. After treatment, cells were washed with PBS and incubated in 100 µl of 5 mg/ml MTT solution (Invitrogen Inc., USA) for 3 h. MTT is converted into purple colored formazan in living cells which was then solubilized with dimethylsulfoxide (DMSO) (Invitrogen Inc., USA) for 3 h. MTT assay was performed using 70-80% confluent cultures.

Cell cycle analysis. After treatment, cells were harvested, trypsinized and rinsed 3 times with buffer solution with adjusted concentration of 1x10⁶ cells/ml and prepared using CycleTest™ Plus DNA Reagent kit (Becton-Dickinson, USA) according to the manufacturer's instructions. Cell cycle status was analyzed by flow cytometer using propidium iodide (PI) as a specific fluorescent dye probe. The PI fluorescence intensity of 10,000 cells was measured for each sample using a Becton-Dickinson FACSCalibur flow cytometer.

Cell apoptosis assay. Cell apoptosis was determined by Annexin V assay. After transfection for 48 h, cells were harvested by trypsinization and washed with PBS, and suspended in Annexin V binding buffer. FITC-conjugated Annexin V and propidium iodide (PI; Beyotime, China) were added to the cells successively. After incubation, Annexin V binding buffer was added, and cells were analyzed by a FACScan (Becton-Dickinson) flow cytometry. Annexin V(+)/P(-) and Annexin V(+)/P(+) represent the cells in early apoptosis and late apoptosis/necrosis, respectively.

Cell migration and invasion assay. Cell migration and invasion were assayed using a Transwell chamber (Millipore, USA). For the invasion assay, Transwell chamber was coated with 30 µl Matrigel and was placed into 24-well plate and incubated for 30 min at 37°C. After 48 h of transfection, HepG2 cells were trypan blue stained and seeded in chambers at the density of 8x10⁴ cells per well and cultured in medium with RPMI-1640 medium with 2% serum, while 600 µl of 10% FBS-RPMI-1640 with or without TGF-β (10 ng/ml) was added to the lower chamber. Twenty-four hours later, migrated cells were fixed with 100% methanol for 30 min and stained by crystal violet for 20 min. Non-migrated cells were removed by cotton swabs. Cell images were obtained under a phase-contrast microscope (Olympus, Tokyo, Japan).

Electron microscopy. Morphological changes in cells were emulated by scanning electron microscopy. Cells were grown on plastic cover slips. After indicated treatments, fixed in 2.5% glutaraldehyde in phosphate-buffered saline (PBS, pH 7.4) for 2 h, rinsed with PBS, and dehydrated through graded ethanol (30, 50, 70, 80, 90 and 100% for 20 min each). Cells were transferred to amylacetate for 10 min, critical point dried, and then coated with gold. Cells were viewed in a scanning electron microscope (Olympus).

Western blotting. Western blotting was applied to detect markers of EMT at protein level. After indicated treatments, HepG2 cells cultured on the glass slide were washed twice in ice-cold PBS, and then lysed by RIPA buffer with 1% phenylmethanesulfonfluoride (PMSF) and complete protease inhibitor cocktail (Roche Molecular Biochemical, Indianapolis, IN, USA) for 30 min. After centrifugation at 12,000 rpm for 5 min, supernatant was collected and protein concentrations were determined using the Bio-Rad kit (Bio-Rad Laboratories, USA). Cell lysates were separated by SDS-PAGE gel, transferred to polyvinylidene difluoride (PVDF; Millipore). Membranes were blotted with 10% non-fat milk, washed in TBS-Tween and incubated with primary polyclonal antibodies anti-E-cadherin or anti-Vimentin (1:400; Santa Cruz, USA) overnight at 4°C. After washing with TBS-Tween, membranes were incubated with secondary antibody (horseradish peroxidase conjugated IgG) for 60 min at room temperature. Polyclonal anti-GAPDH (1:800; Bioss, China) was used as an internal control. Then, they were washed again with TBS-Tween before using the enhanced chemiluminescence detection system (Amersham Pharmacia Biotech, USA). Blots were imaged by Molecular Image™ ChemiDoc™ XR5+ with Image Lab™ Software (Bio-Rad Laboratories, Inc.).
~5 mm in diameter, tumor volume (V) was measured by caliper daily and calculated using the formula \( V = \frac{L \times W^2}{2} \), where \( L \) was the length and \( W \) was the width of the tumor. The mice were randomly divided into two groups (n=6) for treatment with SFN (50 mg/kg) or vehicle control through i.p. injection every 2 days, respectively. Growth curves were plotted using average tumor volume within each experimental group every 2 days. Thirteen days later, the mice were euthanized, and the dissected tumors were collected and prepared for subsequent analyses. All animal experiments were approved by the animal center.

### Statistical analysis

The data are presented as the mean ± SD from the three independent experiments. Immunoblot signals were quantitated using densitometry and ImageJ software version 1.4 (NIH, USA). Statistical analysis was performed by the SPSS version 18.0 (SPSS Inc., Chicago, IL, USA) using analysis of variance (ANOVA) followed by the Tukey's t-test. \( P<0.05 \) was considered statistically significant.

### Results

**SFN suppresses proliferation of hepatocellular carcinoma HepG2 cells.** The dose and time course of the effect of SFN on cell proliferation was examined by MTT assay (Fig. 1). We found that SFN significantly inhibited cell proliferation of HepG2 in a dose-dependent manner, with an IC\(_{50}\) value of 40.05 µM. HepG2 also responded to SFN in a time-dependent manner. SFN significantly inhibited proliferation of HepG2 cells at 40.05 µM after 48 h. Thus, SFN inhibited the proliferation of hepatocellular carcinoma HepG2 cells both dose- and time-dependently.

**SFN promotes cell cycle arrest and apoptosis in hepatocellular carcinoma HepG2 cells.** As the growth inhibition of cancer cells is usually associated with cell cycle arrest, the effect of SFN on cell cycle distribution of HepG2 was examined (Fig. 2A and B). We found that cell cycle was arrested at the G0/G1 phase when HepG2 cells were treated with 40 µM SFN for 48 h.

Next, we tested the effect of SFN on HepG2 cell apoptosis (Fig. 2C and D). SFN markedly increased both the early and late apoptosis, compared with control.

**SFN changes the morphology and TGF-β-induced EMT of HepG2 cells.** Morphology of HepG2 cells was changed in the presence of SFN (Fig. 3A). SFN suppressed the typical morphology changes of EMT induced by TGF-β, and inhibited the formation of fibroblast-like mesenchymal cells in HepG2 cells.

Phenotypic transition of SFN-inhibited EMT was further evaluated by changes of the mesenchymal marker Vimentin, and the epithelial marker E-cadherin. As expected, SFN significantly suppressed the expression of Vimentin, and significantly elevated the expression of E-cadherin (Fig. 3B). The effect of SFN on the expression of these EMT markers was in a dose-dependent. Overall, SFN inhibited TGF-β-induced EMT of HepG2.

**SFN inhibits HepG2 cell migration and invasion.** Using Transwell assay, the effects of SFN on cell migration and invasive ability was determined (Fig. 4A). We found a significantly decreased number of migrated HepG2 cells treated with 40 µM of SFN (Fig. 4B).

**ROS-dependent mechanism mediated the effect of SFN on EMT in HepG2 cells.** To evaluate whether ROS was involved in TGF-β-induced HepG2 cell migration and invasion, and EMT, ROS scavenger N-acetyl-L-cysteine (NAC, 20 mM) was added to treat the HepG2 cells for 24 h in the present of TGF-β (Fig. 4C-E). The inhibitory effect of SFN on migration and invasion were almost completely abolished by NAC in HepG2 cells (Fig. 4C and D). Also, NAC abolished the decrease of Vimentin, and the increase of E-cadherin (Fig. 4E). It was suggested that ROS-dependent mechanism mediated the effect of SFN on EMT of HepG2 cells.

**SFN suppresses xenograft tumor growth.** We showed a significant inhibitory effect of SFN on cell growth of HepG2 cells. Here, we further determined the effect of SFN on the growth of HepG2 cell-derived xenograft tumors in nude mice (Fig. 5). HepG2 cell-derived xenograft tumor grew slowly in the mice treated with 50 mg/kg SFN, whereas grew progressively in the control mice with a larger tumor volume than the SFN group. Taken together, our results indicate that SFN is an effective agent for hepatocellular carcinoma treatment.
Figure 2. SFN induces hepatocellular carcinoma cell cycle arrest and cell apoptosis. HepG2 cells were treated with 40 µM SFN or vehicle control for 48 h. Then, (A) the cell cycle distribution was measured by flow cytometry, and (B) the cell cycle phase is shown in a bar graph with the G0/G1, S, and G2/M phases. (C) Cell apoptosis was determined using the Annexin V-FITC/PI flow cytometry, and (D) proportion of apoptosis cells was measured. *P<0.05 vs. vehicle control.
Discussion

SFN has been widely used for treatment of inflammatory diseases in vitro and in vivo (17-20). In a previous clinical study conducted on healthy volunteers (27), it was reported that no obvious abnormal events (toxicities) were observed, suggesting the safety of SFN for humans. Recent studies on the role of SFN in cancer progression indicated an antitumor effect of SFN. SFN has been reported to suppress proliferation and diverse cancer cells by causing apoptosis, cell cycle arrest, or both (28). Furthermore, SFN influenced the cell growth and metastasis in diverse cancers, including thyroid cancer (17), breast cancer (19), colon cancer (21,22), prostate cancer (18), bladder cancer (23,24) and leukemia (25). SFN inhibited cell growth and invasiveness of thyroid cancer, and promoted mitochondrial-mediated apoptosis via reactive oxygen species (ROS)-dependent pathway (17). SFN induces apoptosis in bladder cancer cells through the ROS-mediated mitochondrial pathway (23,24). However, the antitumor effect of SFN on hepatocellular carcinoma remains incompletely understood. It was demonstrated that SFN induces the generation of ROS in hepatoma cells, and sensitize many tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis by upregulating DR5 (29). ROS has been reported to mediate many cellular effects of hepatoma cells, including the EMT of HepG2 cells induced by the tumor promoter 12-O-tetradecanoyl phorbol-13-acetate (26). Our present study demonstrates that SFN significantly suppressed hepatocellular carcinoma cell growth in vitro and in vivo, and the migration, invasion and EMT of hepatocellular carcinoma cells.

As reported (17), the exact mechanism of the potent antitumor effect of SFN on cancer cells is still unclear, and the mechanism of SFN in cell cycle and apoptosis seems very complex. In T-cell leukemia and melanoma cells, SFN could induce a positive effect on p53 expression with a consequent decrease in Bcl-2 and increase in Bax (30,31), whereas it is not required for the SFN activity in leukemia u937 cells and colon cancer cells (25,32). In SFN-treated thyroid cancer cells, the cells were arrested in G2/M phase, which was mediated by a ROS-dependent pathway, but not a p53-dependent mechanism (17). In this study, our results showed that the cell proliferation of HepG2 were significantly decreased by treatment of SFN for 48 h, the 50% inhibitory concentrations (IC50) for HepG2 cells was 40.05 mM. By using 40 mM SFN, the observations suggested that SFN suppressed cell proliferation of HepG2 with treatment concentration and suppressed cell growth by decreasing the cells in S phase. SFN-treated HepG2 cells were arrested in G0/G1 phase. SFN also promoted cell apoptosis. However, the underlying mechanism is still unclear, further studies will be necessary to determine the changes in p53

Figure 3. SFN inhibits TGF-β-induced EMT of hepatocellular carcinoma cells. TGF-β (10 ng/ml) was used to induce EMT of HepG2 cells. After 24 h, an additional 40 µM SFN and/or 20 mM NAC was used to treat the cells for another 48 h. (A) Morphological changes in normal cultured HepG2 cells; TGF-β stimulated HepG2 cells; SFN-treated HepG2 cells; TGF-β-stimulated HepG2 cells in the presence of SFN. (B) E-cadherin and Vimentin were detected by western blotting, to evaluate the effect of SFN on the EMT process of HepG2 cells by TGF-β.
Figure 4. Effect of SFN and NAC on the TGF-β-induced EMT of hepatocellular carcinoma cells. TGF-β (10 ng/ml) was used to induce the EMT of HepG2 cells. After 24 h, an additional of 40 µM SFN and/or 20 mM NAC was used to treat the cells for another 48 h. (A) Migration and invasion was assessed using Transwell chamber and (B) migrated cells were counted. **P<0.01 vs. vehicle control. SFN inhibits hepatocellular carcinoma cell migration and invasion. (C) Migration and invasion was assessed using Transwell chamber and (D) migrated cells were counted. **P<0.01 vs. control. NAC abolished the inhibition of migration and invasion by SFN. (E) E-cadherin and Vimentin were detected by western blotting, to evaluate the effect of SFN with NAC on EMT process of HepG2 by TGF-β.

Figure 5. SFN inhibited the xenograft tumor growth. (A) Representative images of tumor growth in mice treated with control (vehicle) and 45 mg/kg of SFN. (B) Time course of the tumor volume (V) was measured by caliper daily and calculated using the formula V=(LxW²)/2, where L was the length and W was the width of the tumor.
proteins and ROS signaling pathway by which sulforaphane induces the cell arrest and cell apoptosis in hepatocellular carcinoma.

In recent years, EMT has been highlighted to be involved in cancer progression (33). The process of EMT is characterized as the loss of epithelial phenotype and the gain of mesenchymal phenotype (34). A recent study has showed that SFN inhibited hepatocellular carcinoma cell proliferation, migration and invasion, as well as EMT via a ROS-dependent pathway. The effect of SFN on the growth of hepatocellular carcinoma cells was confirmed by the xenograft tumor growth model. All our finding implicated that SFN is a promising and safe strategy for treating hepatocellular carcinoma.

Acknowledgments

This work was supported in part by the Key Project of Hainan Province, China (no. 1321320 and 67A1006) and by the Scientific Research Project of Hainan Provincial Health Department (no. Qiongwei-2012pt-92).

References